| Zhang, Wei |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression |
|
|
| Recruiting | 2 | 260 | RoW | Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule | Tasly Pharmaceutical Group Co., Ltd | Depression | 04/25 | 04/25 | | |
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL |
|
|
| Not yet recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 08/24 | 02/27 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05577091: Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 10 | RoW | Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes., Autologous Tris-CAR-T cell. | Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Tasly Pharmaceutical Group Co., Ltd | Recurrent Glioblastoma | 11/24 | 11/32 | | |
NCT05634473: A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test |
|
|
| Not yet recruiting | N/A | 280 | RoW | Methacholine Chloride | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Asthma | 02/23 | 06/23 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Freeman, Michael |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Zhang, Jun |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04782895: Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age |
|
|
| Completed | 3 | 488 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 05/22 | 07/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05056402: An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old |
|
|
| Active, not recruiting | 3 | 1382 | RoW | 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli) | Xiamen Ophthalmology Center Affiliated to Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 12/25 | 12/25 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04537156: Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) |
|
|
| Active, not recruiting | 3 | 9327 | RoW | Nonavalent HPV vaccine, Bivalent HPV vaccine | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata | 12/27 | 12/27 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis |
|
|
| Recruiting | 2 | 116 | RoW | Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors | 12/23 | 12/24 | | |
NCT02710851: Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine |
|
|
| Active, not recruiting | 2 | 640 | NA | low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1), Hepatitis E vaccine,Hecolin® | Jun Zhang, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Condylomata Acuminata | 12/23 | 12/23 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
| Not yet recruiting | 2 | 40 | US | Cabozantinib, Cabometyx, Atezolizumab, Tecentriq | Jun Zhang, MD, PhD, Exelixis, Genentech, Inc. | Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC | 06/26 | 06/28 | | |
| Recruiting | 2 | 90 | Europe, US, RoW | Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin | Mirati Therapeutics Inc. | Advanced NSCLC, Metastatic Lung Cancer | 06/26 | 12/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 125 | US | DSP107, Atezolizumab | Kahr Medical | Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05068856: A Study of HRS2543 in Patients With Advanced Tumors |
|
|
| Terminated | 1 | 10 | RoW | HRS2543 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Tumors | 05/24 | 05/24 | | |
NCT05537987: Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 30 | US | ICP-723 | InnoCare Pharma Inc. | Advanced Solid Tumors | 11/23 | 07/24 | | |
NCT04911166: Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy |
|
|
| Suspended | 1 | 13 | US | Atezolizumab and Interleukin-12 Gene Therapy | The Methodist Hospital Research Institute, Genentech, Inc. | Non-small Cell Lung Cancer | 08/24 | 03/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
NCT06197802: Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women |
|
|
| Active, not recruiting | N/A | 392 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 03/25 | 03/25 | | |
| Recruiting | N/A | 25 | US | Standard of care immune checkpoint inhbitors | Jun Zhang, MD, PhD, Nilogen Oncosystems | Lung Cancer, NSCLC, NSCLC Stage IV | 01/26 | 02/27 | | |
HPV-PRO-006-4, NCT06243666: Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls |
|
|
| Not yet recruiting | N/A | 2188 | RoW | Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), No intervention | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China | Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection | 12/26 | 12/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Zhao, Yong |
NCT04011020: Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes |
|
|
| Recruiting | 2/3 | 50 | US | Stem Cell Educator therapy | Throne Biotechnologies Inc., Hackensack Meridian Health | Type 1 Diabetes | 10/24 | 06/25 | | |
NCT04011748: Clinical Application of Stem Cell Educator Therapy in Alopecia Areata |
|
|
| Recruiting | 2 | 20 | US | Stem Cell Educator therapy | Throne Biotechnologies Inc. | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 07/23 | 07/23 | | |
| Zhou, Huimin |
NCT05426018: The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 200 | RoW | SY-009 capsules | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Type 2 Diabetes | 06/23 | 10/23 | | |
| Liu, Gang |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06672276: To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency |
|
|
| Not yet recruiting | 1 | 32 | RoW | TQD3606 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria | 05/25 | 11/25 | | |
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease |
|
|
| Recruiting | N/A | 286 | RoW | DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease | 06/22 | 04/23 | | |
| Gu, Ping |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT03550183: Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease |
|
|
| Enrolling by invitation | 1 | 20 | RoW | mesenchymal stem cells | Hebei Newtherapy BIo-Pharma technology Co., Ltd. | Parkinson's Disease | 10/22 | 12/22 | | |
| Wang, Yanyong |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Zhang, Lina |
NCT06351150: Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock |
|
|
| Not yet recruiting | 3 | 214 | RoW | Angiotensin II Injection, 0.9% sodium chloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Vasodilatory Shock | 06/27 | 12/27 | | |
NCT05707832: A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus |
|
|
| Not yet recruiting | 3 | 60 | RoW | Amphotericin B cholesteryl Sulfate Complex for Injection | CSPC Ouyi Pharmaceutical Co., Ltd. | Invasive Candidiasis, Invasive Aspergillosis | 08/25 | 12/25 | | |
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL |
|
|
| Recruiting | 1/2 | 84 | RoW | ATG-010, Selinexor, Lenalidomide, Rituximab | Antengene Corporation | Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | 03/25 | 06/25 | | |
| Zhang, Lei |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05888870: ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor |
|
|
| Recruiting | 4 | 50 | RoW | SCT800 and Daratumumab, Immune tolerance induction combine anti-CD38, SCT800, Immune tolerance induction only | Institute of Hematology & Blood Diseases Hospital, China, Sinocelltech Ltd. | Hemophilia A With Inhibitor | 12/26 | 12/26 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05487976: Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor |
|
|
| Recruiting | 3 | 50 | RoW | Recombinant human activated coagulation factor VII for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A, Hemophilia B | 04/23 | 04/23 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05619926: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor |
|
|
| Completed | 2 | 32 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Novikang Medical Technology Co., LTD | Hemophilia | 08/23 | 08/23 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT06552429: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET |
|
|
| Recruiting | 2 | 27 | RoW | Peginterferon α-2b injection | Xiamen Amoytop Biotech Co., Ltd. | Essential Thrombocythemia | 09/25 | 09/27 | | |
NCT06594146: Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) |
|
|
| Not yet recruiting | 2 | 60 | NA | CM313 injection, placebo | Keymed Biosciences Co.Ltd | Primary Immune Thrombocytopenia | 12/25 | 12/25 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05027230: A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1/2 | 77 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 07/23 | 07/23 | | |
NCT06111638: Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs |
|
|
| Recruiting | 1/2 | 12 | RoW | Single dose intravenous injection of BBM-H803 | Shanghai Belief-Delivery BioMed Co., Ltd, Shanghai MYGT Biopharmaceutical LLC | Hemophilia A | 06/26 | 06/30 | | |
NCT04747964: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1 | 16 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 04/21 | 04/21 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
NCT05217459: The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease |
|
|
| Completed | N/A | 128 | RoW | Self-expanding intracranial drug stent system | Sinomed Neurovita Technology Inc., Changhai Hospital | Intracranial Arterial Diseases, Stent Restenosis, Percutaneous Transluminal Angioplasty | 08/23 | 03/24 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
| Completed | N/A | 34 | US, RoW | SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System | Boston Scientific Corporation | Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease | 12/24 | 01/25 | | |
NCT05442528: Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study |
|
|
| Not yet recruiting | N/A | 20 | NA | | Shanghai Vitalgen BioPharma Co., Ltd. | Hemophilia B | 12/24 | 12/24 | | |
| Wang, Yao |
NCT03569280: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients |
|
|
| Completed | 1 | 16 | US | Enzalutamide or Abiraterone or Apalutamid | Kangpu Biopharmaceuticals, Ltd. | Castration-Resistant Prostate Cancer | 01/23 | 06/23 | | |
| Liu, Li |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Completed | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 11/24 | 11/24 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 3000 | US | Treatment Recommendation Surveys, 7-gene biosignature | PreludeDx, University of South Florida | DCIS | 12/25 | 12/35 | | |
| Lei, Zhang |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT04768699: Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. |
|
|
| Recruiting | 1 | 24 | RoW | TQG203, TQG203/NovoSeven® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 12/21 | 12/21 | | |
| Shen, Yang |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen |
|
|
| Recruiting | 2 | 83 | RoW | Efbemalenograstim Alfa | Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ovarian Cancer, Cervical Cancer | 06/26 | 12/26 | | |
| Zhao, Dan |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
